Business Context and Reporting Period
Company: United Therapeutics Corporation (UTHR)
Filing Type: Form 8-K (Current Report)
Date of Report: January 21, 2026
Reporting Period: Events occurring on January 21, 2026
This filing reports corporate governance changes, including the appointment of a new director and amendments to the Company's Bylaws.
Key Financial Metrics
This Form 8-K does not contain financial performance data. The filing text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
Board of Directors Appointment
- The Board size was increased to 13 members.
- Kevin J. Tracey, M.D. was appointed as a new member of the Board.
- Dr. Tracey will not initially serve on any Board committee.
- No material transactions exceeding $120,000 exist between Dr. Tracey and the Company since the beginning of the last fiscal year.
Compensation Arrangements
- Dr. Tracey was awarded 1,220 restricted stock units (RSUs) under the 2015 Stock Incentive Plan.
- Awards were granted on January 21, 2026, consistent with the standard non-employee director compensation program.
- A standard indemnification agreement was executed effective January 21, 2026.
Bylaws Amendments
The Board approved the Eleventh Amended and Restated Bylaws, effective immediately. Key changes include:
- Shareholder Nomination Cure Process: Implementation of a process to notify shareholders of deficiencies in nomination notices and allow time to cure them (Sections 2.5 and 2.14).
- Voting Thresholds: Removal of language allowing the Board to require a vote larger than a majority for elections or questions (Section 2.9).
- Bylaw Amendment Threshold: Lowered the required stockholder vote to amend Bylaws from 80% to a majority of voting power (Section 9.6).
Guidance, Outlook, and Risks
This filing does not contain financial guidance, outlook, or management commentary regarding future performance. No specific risks or contingencies related to financial operations are disclosed in this document.
Investor Verification Checklist
- Verify the full text of the Eleventh Amended and Restated Bylaws (Exhibit 3.1) to understand the specific mechanics of the new cure process and voting thresholds.
- Review the Press Release (Exhibit 99.1) for additional context on Dr. Tracey's appointment and qualifications.
- Confirm the impact of the reduced Bylaw amendment threshold (from 80% to majority) on future shareholder proposals.
- Check the Company's definitive proxy statement for the 2025 annual meeting for details on the Director Compensation Program referenced in the RSU grant.